In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization.
Level V
Where this comes from
- Record sourced from PubMed, PMID 33197352.
- Also identified by DOI 10.7326/ACPJ202011170-051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Packer M, Anker SD, Butler J, et al. <b>Cardiovascular and renal outcomes with empagliflozin in heart failure.</b> N Engl J Med. 2020;383:1413-24. 32865377.
Medical subject headings
- Diabetes Mellitus, Type 2
- Heart Failure